Trial reportThe European respiratory journal2021
Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma.
Trial report in The European respiratory journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02414854 (A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Dupilumab efficacy and safety in patients with moderate to severe asthma: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Unknotting the nexus of asthma and neuroinflammation: from brain network alterations to therapeutic implications.Journal of neuroinflammation · 2026Review
- Metabolic licensing at the dendritic cell-NK cells immune synapse in viral asthma exacerbations.Frontiers in immunology · 2026Review
- Challenges and Opportunities in Achieving Asthma Remission.Journal of clinical medicine · 2025Review
- Impact of Exacerbation History on Dupilumab Efficacy in Children with Uncontrolled Moderate-to-Severe Asthma: LIBERTY ASTHMA VOYAGE Study.Journal of asthma and allergy · 2024Article
- Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma.ERJ open research · 2023Article
- Cytokine-targeted therapies for asthma and COPD.European respiratory review : an official journal of the European Respiratory Society · 2023Review
- Promising treatment biomarkers in asthma.Frontiers in drug safety and regulation · 2023Review
- A pragmatic guide to choosing biologic therapies in severe asthma.Breathe (Sheffield, England) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe phase 3 LIBERTY ASTHMA QUEST study (ClinicalTrials.gov: NCT02414854) in patients with uncontrolled, moderate-to-severe asthma has demonstrated the efficacy and safety of dupilumab 200 and 300 mg every 2 weeks
methodsAnnualised severe exacerbation rates over the 52-week treatment period, pre-bronchodilator forced expiratory volume in 1 s (FEV
resultsAcross all type 2-high subgroups, dupilumab
conclusionsDupilumab significantly reduced severe exacerbations and improved FEV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.